Status | Study |
Recruiting |
Study Name: A Natural History of Late Onset Tay-Sachs Disease Condition: GM2 Gangliosidosis Date: 2016-07-19 |
Recruiting |
Study Name: Biomarker for GM1/GM2 - Gangliosidoses Condition: Gangliosidosis GM1-Gangliosidosis Date: 2014-10-23 |
Recruiting |
Study Name: UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells Condition: Adrenoleukodystrophy Batten Disease Mucopolysaccharidosis Date: 2014-09-23 Interventions: Biological: DUOC-01 Intrathecal administration of DUOC-01 |
Recruiting |
Study Name: Synergistic Enteral Regimen for Treatment of the Gangliosidoses Condition: GM1 Gangliosidoses GM2 Gangliosidoses Date: 2013-12-17 Interventions: Drug: miglustat The Syner-G th |
Active, not recruiting |
Study Name: Efficacy Study of an Online Educational Module Before Carrier Genetic Screening in Persons of Ashkenazi Jewish Descent. Condition: Tay Sachs Disease Canavan Disease Familial Dysautonomia Date: 2013-11-25 Interventions: Other: Online pre-test genetic education tool See Arm Descriptions above. |
Completed |
Study Name: Gene Therapy for Tay-Sachs Disease Condition: Tay Sachs Disease Sandhoff Disease Late Onset Tay Sachs Di Date: 2013-05-22 |
Completed |
Study Name: Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal Disorders Condition: Lysosomal Storage Disease Peroxisomal Disorder Date: 2012-06-20 Interventions: Drug: Campath-1H A daily dose |
Active, not recruiting |
Study Name: Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders Condition: Hurler Syndrome (MPS I) Hurler-Scheie Syndrome With Early Neurologic Involvement and/or Sens Date: 2011-06-10 Interventions: Biological: FCRx infusion Enriched hematopoetic stem cell infusion |
Withdrawn |
Study Name: Fetal Umbilical Cord Blood (UCB) Transplant for Lysosomal Storage Diseases Condition: Lysosomal Storage Diseases Inborn Errors of Metabolism Date: 2009-10-20 Interventions: Biological: ALD-601 ALD-601 is manufactured by Aldagen from the 20% compartment of the selected umbilica |
Completed |
Study Name: Pyrimethamine as a Treatment for Late-Onset GM2-gangliosidosis (Tay-Sachs and Sandhoff Disease) Condition: Gangliosidoses, GM2 Sandhoff Disease Date: 2009-10-16 Interventions: Drug: Pyrimethamine Pyrimetham |